FreeTheAI

Tempest Therapeutics Appoints Former Skillsoft CFO John W. Frederick to Board

NeutralLow impact
TPST$0.6813 −8.27%

Tempest Therapeutics, Inc. (NASDAQ:TPST) has appointed John W. Frederick to its board of directors. Frederick brings more than three decades of experience in corporate finance, capital markets, and corporate governance across public and private companies.

The addition comes as the clinical-stage biotechnology company focuses on disciplined capital allocation and advances its core pipeline. Frederick previously served as chief financial officer at Skillsoft and held senior financial and operational leadership roles at Indigo Ag and Snagajob. His background in managing capital structures and financial strategy is intended to support the firm as it works toward key development milestones.

Investors will be watching how the board expansion supports the development of Tempest's lead candidate, TPST-4003, an in vivo CAR-T therapy targeting cancer and autoimmune disease. Meanwhile, shares of Tempest Therapeutics fell 8.27 percent to $0.6813 in recent trading.

Key points

  • Tempest Therapeutics, Inc. (NASDAQ:TPST) appointed John W. Frederick to its board of directors.
  • Frederick brings over 30 years of financial experience, including prior roles as chief financial officer at Skillsoft.
  • The company is advancing its lead product candidate, TPST-4003, for cancer and autoimmune conditions.
  • Shares of Tempest Therapeutics dropped 8.27 percent to $0.6813 on the day of the announcement.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

Who was appointed to the board of Tempest Therapeutics?

John W. Frederick was appointed to the board of directors at Tempest Therapeutics. He brings over three decades of experience in corporate finance, including serving as chief financial officer at Skillsoft.

What does Tempest Therapeutics do?

Tempest Therapeutics is a clinical-stage biotechnology company developing in vivo CAR-T therapies to treat cancer and autoimmune diseases. Its lead candidate is TPST-4003.

What is the ticker symbol and stock price for Tempest Therapeutics?

Tempest Therapeutics trades on the NASDAQ under the ticker symbol TPST. Following the announcement, the stock dropped 8.27 percent to $0.6813.